Market Challenges And Opportunities

Endometriosis Treatment Market Drivers:-

Increasing research activities for development of new drugs for the global endometriosis treatment market is expected to be a major driver for growth of the market over the forecast period. For instance in 2017, AbbVie, biopharmaceutical company in co-operation with Neurocrine Biosciences Inc submitted New Drug Application (NDA) to the U.S. Food and drug Administration (FDA) for a new drug named elagolix. It is an orally administering gonadotropin releasing hormone antagonist, which is being evaluated for management of pain associated with endometriosis.

Launch of products by manufacturer is also expected to drive global endometriosis treatment market growth. For instance, in 2018, LASCO distributors in association with Bayer healthcare launched new drug visanne, which is indicated for endometriosis treatment.

Other factors such as increase in prevalence of endometriosis, robust pipeline, awareness about endometriosis is expected to support endometriosis treatment market growth. For instance, Triptoreline sponsored by University Hospital, Rouen is in Phase 3 Clinical Trials; Triptoreline cures deep endometriosis in the rectum , Myovant Sciences has Relugolix in phase 3 Clinical Trials; Relugolix ceases non-menstrual pelvic pain, Indocyannine Green sponsored by University Hospital in Phase 4 Clinical Trials; Indocyannine Green treats recto vaginal endometriosis, Dienogest sponsored by the University Of Hong Kong is in Phase 4 Clinical Trials; dienogest stops the reoccurance of endometriosis cyst, Merional sponsored by Cario University is in phase 3 Clinical Trials; Merional controls intrauterine insemination cycles in women having endometriosis.

According to a survey conducted by National Center for Biotechnology Information (NCBI), 2014, endometriosis is estimated to affect 10% of female in the reproductive age and more than 50% in infertility patients, which in turn is expected to fuel growth of the endometriosis treatment market over the forecast period.